Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.

On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...

Merck & Co. Inc.’s stock rose 2% premarket Tuesday, after the company reported positive results for a new, ...

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck (MRK) stock gains as its subcutaneously delivered pembrolizumab meets key goals in Phase 3 trial against intravenous ...

In a significant move towards the liberalization of the healthcare sector, Shanghai's Pudong New Area witnessed the first ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Within 10 years of Crohn's disease diagnosis, up to 50% of people will require surgery, with ileocaecal or ileocolonic resection being the most common procedure.1 Surgery is not curative and disease ...